{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:14:57Z","timestamp":1792782897293,"version":"4.5.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,12,27]],"date-time":"2022-12-27T00:00:00Z","timestamp":1672099200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,12,27]],"date-time":"2022-12-27T00:00:00Z","timestamp":1672099200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Zurich University Foundation"},{"DOI":"10.13039\/501100006447","name":"University of Zurich","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006447","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2023,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To explore the impact of the human leucocyte antigen (HLA)-B27 on the effectiveness of tumor necrosis factor inhibitors (TNFi) in patients with axial spondyloarthritis (axSpA).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A total of 1109 patients with available HLA-B27 status (831 B27+ patients and 278 B27\u2212 patients) fulfilling the Assessment of Spondyloarthritis international Society classification criteria for axSpA from the prospective Swiss Clinical Quality Management Registry initiating a first TNFi were included. Drug retention was investigated with multiple adjusted Cox proportional hazard models with imputation of missing values. Multiple-adjusted logistic regression analyses were used to assess the proportion of patients reaching 50% reduction in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI50) at 1 year.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>B27+ and B27\u2212 patients differed with regard to age, sex, BASDAI, C-reactive protein (CRP), body mass index, enthesitis, uveitis, and classification status. After adjustment for potential confounders for the relationship between HLA-B27 and drug effectiveness (sex and family history of spondyloarthritis), a higher risk of drug discontinuation was found in B27\u2212 patients (HR 1.53, 95% CI 1.27\u20131.83). This difference decreased after additional adjustment for parameters which may act as mediators (HR 1.30, 95% CI 1.30\u20131.55). Male sex and elevated C-reactive protein (CRP) levels were consistently associated with longer retention. Comparable results were obtained for BASDAI50 responses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The HLA-B27 genotype is an important predictor of treatment effectiveness. Male sex and CRP seem, however, to better describe variability of response in individual patients. This data may help avoiding potential discrimination of B27\u2212 individuals with regard to TNFi initiation.<\/jats:p>\n                    <jats:p>\n                      <jats:table-wrap>\n                        <jats:table>\n                          <jats:tbody>\n                            <jats:tr>\n                              <jats:td colspan=\"2\">\n                                <jats:bold>Key Points<\/jats:bold>\n                                \u2022\n                                <jats:italic>HLA-B27 is a predictor of effectiveness of TNF inhibitors in axial spondyloarthritis.<\/jats:italic>\n                                \u2022\n                                <jats:italic>Variability of response in individual patients is better defined by sex and objective markers of disease activity, such as C-reactive protein.<\/jats:italic>\n                              <\/jats:td>\n                            <\/jats:tr>\n                          <\/jats:tbody>\n                        <\/jats:table>\n                      <\/jats:table-wrap>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10067-022-06490-8","type":"journal-article","created":{"date-parts":[[2022,12,27]],"date-time":"2022-12-27T01:02:41Z","timestamp":1672102961000},"page":"1267-1274","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["HLA-B27 as a predictor of effectiveness of treatment with TNF inhibitors in axial spondyloarthritis: data from the Swiss Clinical Quality Management Registry"],"prefix":"10.1007","volume":"42","author":[{"given":"Fabienne","family":"Fr\u00f6hlich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8918-7304","authenticated-orcid":false,"given":"Raphael","family":"Micheroli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Hebeisen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0619-0012","authenticated-orcid":false,"given":"Seraphina","family":"Kissling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"B\u00fcrki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascale","family":"Exer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren\u00e9","family":"Br\u00e4m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Niedermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Burkhard","family":"M\u00f6ller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Nissen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Kyburz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Andor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Distler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Almut","family":"Scherer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7870-7132","authenticated-orcid":false,"given":"Adrian","family":"Ciurea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,27]]},"reference":[{"key":"6490_CR1","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1056\/NEJM197304052881403","volume":"88","author":"L Schlosstein","year":"1973","unstructured":"Schlosstein L, Terasaki PI, Bluestone R, Pearson CM (1973) High association of an HL-A antigen, W27, with ankylosing spondylitis. N Engl J Med 88:704\u2013706","journal-title":"N Engl J Med"},{"key":"6490_CR2","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/S0140-6736(73)91360-3","volume":"1","author":"DA Brewerton","year":"1973","unstructured":"Brewerton DA, Cavrey M, Hard FD (1973) Ankylosing spondylitis and HL-A27. Lancet 1:904\u2013907","journal-title":"Lancet"},{"key":"6490_CR3","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1146\/annurev-immunol-032414-112110","volume":"33","author":"P Bowness","year":"2015","unstructured":"Bowness P (2015) HLA-B27. Annu Rev Immunol 33:29\u201348","journal-title":"Annu Rev Immunol"},{"key":"6490_CR4","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/j.berh.2018.07.012","volume":"31","author":"RA Colbert","year":"2017","unstructured":"Colbert RA, Navid F, Gill T (2017) The role of HLA-B*27 in spondyloarthritis. Best Pract Res Clin Rheumatol 31:797\u2013815","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"6490_CR5","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1007\/s11926-017-0654-8","volume":"19","author":"N Akkoc","year":"2017","unstructured":"Akkoc N, Yarkan H, Kenar G, Khan MA (2017) Ankylosing spondylitis: HLA-B*27-positive versus HLA-B*27-negative disease. Curr Rheumatol Rep 19:26","journal-title":"Curr Rheumatol Rep"},{"key":"6490_CR6","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1093\/rheumatology\/kex345","volume":"57","author":"CSE Lim","year":"2018","unstructured":"Lim CSE, Sengupta R, Gaffney K (2018) The clinical utility of human leucocyte antigen B27 in axial spondyloarthritis. Rheumatology (Oxford) 57:959\u2013968","journal-title":"Rheumatology (Oxford)"},{"key":"6490_CR7","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1136\/ard.2010.147744","volume":"70","author":"N Vastesaeger","year":"2011","unstructured":"Vastesaeger N, van der Heijde D, Inman RD, Wang Y, Deodhar A, Hsu B, Rahman MU, Dijkmans B, Geusens P, Vander Cruyssen B, Collantes E, Sieper J, Braun J (2011) Predicting the outcome of ankylosing spondylitis therapy. Ann Rheum Dis 70:973\u2013981","journal-title":"Ann Rheum Dis"},{"key":"6490_CR8","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.3899\/jrheum.141278","volume":"42","author":"X Baraliakos","year":"2015","unstructured":"Baraliakos X, Koenig AS, Jones H, Szumski A, Collier D, Bananis E (2015) Predictors of clinical remission under anti-tumor necrosis factor treatment in patients with ankylosing spondylitis: pooled analysis from large randomized clinical trials. J Rheumatol 42:1418\u20131426","journal-title":"J Rheumatol"},{"key":"6490_CR9","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2014-000017","volume":"1","author":"JR Maneiro","year":"2015","unstructured":"Maneiro JR, Souto A, Salgado E, Mera A, Gomez-Reino JJ (2015) Predictors of response to TNF antagonists in patients with ankylosing spondylitis and psoriatic arthritis: systematic review and metaanalysis. RMD Open 1:e000017","journal-title":"RMD Open"},{"key":"6490_CR10","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1136\/ard.2003.016386","volume":"63","author":"M Rudwaleit","year":"2004","unstructured":"Rudwaleit M, Listing J, Brandt J, Braun J, Sieper J (2004) Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis. Ann Rheum Dis 63:665\u2013670","journal-title":"Ann Rheum Dis"},{"key":"6490_CR11","doi-asserted-by":"publisher","first-page":"2136","DOI":"10.1002\/art.21913","volume":"54","author":"D Van der Heijde","year":"2006","unstructured":"Van der Heijde D, Kivitz A, Schiff MH, Sieper J, Dijkmans BA, Braun J, Dougados M, Reveille JD, Wong RL, Kupper H, Davis JC Jr, ATLAS Study Group (2006) Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 54:2136\u20132146","journal-title":"Arthritis Rheum"},{"key":"6490_CR12","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1136\/annrheumdis-2012-201766","volume":"72","author":"J Sieper","year":"2013","unstructured":"Sieper J, van der Heijde D, Dougardos M, Mease PJ, Maksymowych WP, Brown MA, Arora V, Pangan AL (2013) Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1). Ann Rheum Dis 72:815\u2013822","journal-title":"Ann Rheum Dis"},{"key":"6490_CR13","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1002\/art.38721","volume":"66","author":"M Dougados","year":"2014","unstructured":"Dougados M, van der Heijde D, Sieper J, Braun J, Maksymowych WP, Citera G, Miceli-Richard C, Cheng-Chung Wei J, Pedersen R, Bonin R, Rahman MU, Logeart I, Wajdula J, Koenig AS, Vlahos B, Alvarez D, Bukowski JF (2014) Symptomatic efficacy of etanercept and its effects on objective signs of inflammation in early nonradiographic axial spondyloarthritis: a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheumatol 66:2091\u20132102","journal-title":"Arthritis Rheumatol"},{"key":"6490_CR14","doi-asserted-by":"publisher","first-page":"3096","DOI":"10.1002\/art.38140","volume":"12","author":"A Ciurea","year":"2013","unstructured":"Ciurea A, Scherer A, Exer P, Bernhard J, Dudler J, Beyeler B, Kissling R, Stekhoven D, Rufibach K, Tamborrini G, Weiss B, M\u00fcller R, Nissen MJ, Michel BA, van der Heijde D, Dougados M, Boonen A, Weber U (2013) Tumor necrosis factor \u03b1 inhibition in radiographic and nonradiographic axial spondyloarthritis. Arthritis Rheum 12:3096\u20133106","journal-title":"Arthritis Rheum"},{"issue":"Suppl2","key":"6490_CR15","first-page":"ii1","volume":"68","author":"J Sieper","year":"2009","unstructured":"Sieper J, Rudwaleit M, Baraliakos X, Brandt J, Braun J, Burgos-Vargas R, Dougados M, Hermann K-G, Landew\u00e9 R, Maksymowych W, van der Heijde D (2009) The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis. Ann Rheum Dis 68(Suppl2):ii1\u2013i44","journal-title":"Ann Rheum Dis"},{"key":"6490_CR16","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1136\/ard.2009.108233","volume":"68","author":"M Rudwaleit","year":"2009","unstructured":"Rudwaleit M, van der Heijde D, Landew\u00e9 R, Listing J, Akkoc N, Brandt J, Braun J, Chou CT, Collantes-Estevez E, Dougados M, Huang F, Gu J, Khan MA, Kirazli Y, Maksymowych WP, Mielants H, Sorensen IJ, Ozgocmen S, Roussou E et al (2009) The development of Assessment in SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis 68:777\u2013783","journal-title":"Ann Rheum Dis"},{"key":"6490_CR17","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1136\/annrheumdis-2011-200025","volume":"70","author":"M Van Onna","year":"2011","unstructured":"Van Onna M, Jurik AG, van der Heijde D, van Tubergen A, Heuft-Dorenbosch L, Landew\u00e9 R (2011) HLA-B27 and gender independently determine the likelihood of a positive MRI of the sacroiliac joints in patients with early inflammatory back pain: a 2-year MRI follow-up study. Ann rheum Dis 70:1981\u20131985","journal-title":"Ann rheum Dis"},{"key":"6490_CR18","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.2312","volume":"5","author":"R Wang","year":"2022","unstructured":"Wang R, Dasgupta A, Ward MM (2022) Predicting probability of response to tumor necrosis factor inhibitors for individual patients with ankylosing spondylitis. JAMA Netw Open 5:e222312","journal-title":"JAMA Netw Open"},{"key":"6490_CR19","doi-asserted-by":"publisher","first-page":"59","DOI":"10.3899\/jrheum.160958","volume":"44","author":"B Glintborg","year":"2017","unstructured":"Glintborg B, Sorensen IJ, Ostergaard M, Dreyer L, Mohamoud AA, Krogh NS et al (2017) Ankylosing spondylitis versus nonradiographic axial spondyloarthritis: comparison of tumor necrosis factor inhibitor effectiveness and effect of HLA-B27 status. An observational cohort study from the nationwide DANBIO registry. J Rheumatol 44:59\u201369","journal-title":"J Rheumatol"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-022-06490-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-022-06490-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-022-06490-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,13]],"date-time":"2023-04-13T06:16:23Z","timestamp":1681366583000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-022-06490-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,27]]},"references-count":19,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["6490"],"URL":"https:\/\/doi.org\/10.1007\/s10067-022-06490-8","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,27]]},"assertion":[{"value":"21 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 December 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study has been approved by the Ethics Commission of the Canton of Zurich (KEK-ZH-Nr. 2014-0439) and has been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written informed consent was obtained from all patients.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"AC received honoraria for lectures from AbbVie, Merck Sharp & Dohme, and Novartis. AS received consulting fees from Pfizer and support for attending meetings from Gilead. BM received speaking fees from Jansen and Novartis and support for attending meetings from Pfizer (payments to institution). DK received consulting and\/or speaking fees from Abbvie, Gilead, Eli Lilly, Novartis, and Pfizer. MJN received consulting and\/or speaking fees from Abbvie, Celgene, Eli Lilly, Novartis, and Pfizer. OD received consulting and\/or speaking fees from Abbvie, Amgen, Eli Lilly, and Pfizer. RM received consulting and\/or speaking fees from Abbvie, Eli Lilly, Gilead, and Pfizer. FF, KB, KN, MA, MH, RB, and SK declare they have no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}